Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol no, it's gone below 12 cents now.
So your answer to my question was...? Everyone has an opinion, including the market, and the market is speaking loud and clear after the January PR campaign.
Going back to your hypothetical about Facebook, the facts surrounding Zuckerberg's scheme would determine if the company was culpable in any way and a judge would determine that. Not a message board guru. Secondly, even if Facebook was never found to be involved, the stock would for sure take a hit on the initial news and throughout the trial. That would be called headline risk.
No, it's not irrelevant
Did Llamas buy every share he owns on the open market?
Thanks for clarifying founding. But ownership is funding. Was the second part speculation or do you have a legal background to support that conclusion?
The point was how much of MJNA that Llamas owns. That does affect MJNA, especially if it's found in any way that a single dollar of the mortgage scheme funded MJNA. That's the point he was making.
Most likely, the reason the other poster said, "Meanwhile in the real world..." is due to the fact that your argument was about Llamas' ability in leading the company, which we all know he doesn't do and hasn't for a couple of years. However, your argument should have been about Llamas' ownership of the company to remain logical.
What happened to the "January run" here? I keep seeing PR after PR but the stock keeps taking a beating and the ask never lets up. What's the cause of that?
Just trying to get a better understanding of Kannaway's business. Do they operate similarly to Herbalife where they record their sales as soon as they have their "brand ambassadors" buy product from them and then the "brand ambassadors" turn around and try to re-sell the products to consumers? Basically if an ambassador could only sell half the product, it doesn't matter because Kannaway already sold 100% of the product to the ambassador?
Im free at last! Great to see that news this week. I like how James set that up in the PR. We are guaranteed at least two more PR's before the actual launch of the CBD supplements. 1 to announce the location of the NY event, and 2 to announce the actual launch. This news flow should help to support the price while allowing much needed exposure for new traders/investors.
It's great to see the good guys here not letting this board turn into our partner's board. I'm with the guys that took advantage of the dips yesterday and today.
CN, I tried to shout out to you on the twittersphere while I was locked up, I hope you caught more than just the flu when you went ice fishing! TGIF and cheers to the genuine guys here, this is just the start.
Nothing like waiting until Friday night when no one is paying attention to release news...maybe they are waiting until MLK day on Monday for a bigger audience....
Tick tock...
Crickets... Walkie talkies between pumpers and insiders must not be working
Is the advertised news coming out after the close today like the Anson news?
I wasn't aware the company has been reporting daily sales numbers to the market since it launched the ad campaign. Wait for Q1 results to speak on ad campaign effectiveness. CBD launch is another story, and like everyone else I'm getting tired of waiting to hear news about that. But Q1 sales should be much greater than any previous quarters sales
Uhhhh they literally just started a nationwide ad campaign? *palm-to-forehead* at least get creative with the bashing so there's some entertainment value
Lol at least we're on the same page
Just curious what the correlation is between buying a stock at the ask and a company's financial statements?
Do you have a link that would show the info on the MJNA website is inaccurate?
According to MJNA's website Tripp is still the President at RDH so he's still in charge. Unless of course he's actually not involved anymore, and this is one of those instances of things not being true that's covered in the website's disclaimer.
http://www.medicalmarijuanainc.com/index.php/leadership
***MARKET SAYS SELL THE MJNA NEWS***
It looks like even a weak-long PR ad campaign can not even bolster the price or the volume for this stock. The insiders are running out of ways to sell their massive amounts of shares without crippling the price. MJNA has been selling dreams for 10 years without any kind of realistic sales or growth to speak of. Instead they sell the same snake oil and change the packaging and shell company it comes from. Tread carefully folks.
The country definitely should matter to an investor. The demographics of affected patients, market size, financial ability of patients/insurance in that country. Just because it's been legalized in Brazil doesn't mean that MJNA has or will have a meaningful share of the market. This clearly is not impactful news if you see the share price today. I hope this wasn't the coming news that's been advertised on Facebook MJNA running out of pumping ability
It's too bad the market isn't over the moon about any of this. The market knows that MJNA is a stock scam. The amount of insiders sales and the timing of the sales around the share price action is sickening.
Correct. They don't file anything with the SEC including their financials because they are unaudited. The weird part is the company has been claiming NASDAQ uplisting for years yet filing with the SEC and having an auditor are prerequisites. Total pump job.
Lol must be getting desperate. Publicly traded companies typically just release PR's or 8k's when they have news. They usually don't have to advertise a coming PR on facebook. They must be trying to build an audience for the pump, we all know there definitely won't be an 8k.
See, someone like that should be the CMO of a company that claims to be the leading source of CBD, not two buddies who are dental surgeons that happen to know the CTO (Lekhram Changoer) of 3 pot companies that are all subsidiaries of each other.
Still no rebuttals to serious questions about the leadership of this company. If you look up the page of company leadership on the MJNA website, you will see that not only do they not provide any career/education history for any of them, but you will also see that they all pretty much have the same positions for all the MJNA shell companies. The same CTO, the same CMO/CSO, the same COO, the same directors. All these companies might look different on paper, but it is all one company, one scam, with the same operators pulling the strings. Llamas gets indicted, so he leaves the attorney that is alleged to have helped in his schemes (reference the rip-report link) behind as the CEO. He then becomes CEO of a company that is a majority owner of MJNA. What a convoluted mess. A simple Google search of the leadership of this company reveals that the closet for this company is bursting at the seams full of skeletons.
Lol thanks for the monthly check-in happy new year
That is flawed logic
A stock that is up on light volume is actually a bearish technical sign. I remember learning that in finance 101
I thought Michelle Sides as CEO was supposed to be a breath of fresh air for the company? It was supposed to show that llamas, the other 48% owner was not in control of the company anymore?
Well it looks like Sides and Llamas have been in cahoots for a while now. In fact Sides is still listed as an attorney for a firm that has 1 employee. How many shell companies are tied to Llamas and Sides?
http://www.ripoffreport.com/r/North-American-Companies-LLC/San-Francisco-California-94105/North-American-Companies-LLC-North-American-Acquisitions-Cobalt-One-LLC-Michael-Llamas-686029
Yeah solid argument I'm sure dr van damme has had time to research CBD between dental fillings. Check any other CMO for any other LEGITIMATE publicly traded company. You'll be hard pressed to find one that hasn't done ANY research in the field that the company is involved in. This is such a sloppy excuse for a company it's not even funny. All the subsidiaries have the same chief medical/science officer??? I can tell there is a lot of quality collaborating going on. LOL HAHAHA
Is this news going to be continually delayed like other news that you promise from your "friends" at Anson? And how would you know there is news coming out this week? Are you saying that you are privy to insider information?
LOL. And how much research has he published on CBD?? I'll go ahead answer that for you...NONE. Typically a chief medical officer is an expert in the field that the company is involved in. Obviously this is not the case for MJNA. SCAM ALERT
So the CMO of MJNA is actually a dental surgeon? What makes him an expert in CBD or anything else related to the company for that matter?
He also is conveniently the CMO, CSO, or equivalent for Axim Biotechnologies (another MJNA shell) and CanChew. It kind of looks liable all of these shell companies on paper are actually operating as the same company.
This company belongs on the show American Greed. SCAM, SCAM, SCAM.
http://investing.businessweek.com/research/stocks/people/person.asp?personId=209209995&ticker=MJNA
Verastem Provides Year-End 2014 Update and Outlook for 2015
BOSTON--(BUSINESS WIRE)--
Verastem, Inc., (VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today provided an overview of the Company’s developments in 2014 and outlined upcoming milestones for 2015.
"In 2014, we achieved critical milestones across all of our development programs targeting cancer stem cells,” said Robert Forrester, President and Chief Executive Officer of Verastem. “We remain highly focused on the successful execution of COMMAND for the treatment of patients with mesothelioma, an orphan disease, with VS-6063. We currently have 55 sites open in 13 countries and have enrolled 180 patients. We expect to conduct the pre-specified interim analysis in the second quarter of 2015. We currently remain on track to complete enrollment by the end of 2015. We are seeing activity of VS-6063 across multiple tumor types, including mesothelioma, ovarian cancer, and also now in advanced non-small cell lung cancer. These results continue to increase our confidence in the potential of a successful outcome from COMMAND. Our goal is to achieve the first approval of VS-6063 in mesothelioma and then to broaden its use to many major cancers such as lung, ovarian and breast cancer.”
At the interim analysis of COMMAND, pre-specified efficacy analyses will be conducted and all safety data will be examined by the independent Data Safety Monitoring Board. A decision will be made whether to stop the study early for futility, continue the study as planned in all patients, or enrich the study population based upon the biomarker merlin. This important milestone will define the primary patient population for the registration-directed study.
“The signals of clinical activity and long-term tolerability that we are seeing across the VS-6063 program are encouraging,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “In addition, both VS-4718 and VS-5584 continue to progress well through Phase 1 clinical trials with favorable tolerability profiles and initial signs of clinical activity beginning to emerge.”
2014 Accomplishments
VS-6063 (Oral Focal Adhesion Kinase Inhibitor)
COMMAND (Control Of Mesothelioma with MAinteNance Defactinib) Study currently enrolling in 13 countries
Registration-directed, randomized, double-blind, placebo-controlled study of VS-6063 as a switch maintenance treatment in patients with malignant pleural mesothelioma benefiting from frontline therapy
Primary endpoints are Progression Free Survival (PFS) and Overall Survival (OS). A sample size of 372 subjects will provide 90% power to assess the superiority of PFS, a co-primary efficacy endpoint, with a 1 sided type I error rate of 0.025, assuming a hazard ratio of 0.67.
180 patients enrolled at 55 centers in 13 countries to date. The study is currently accruing on track to complete enrollment by the end of 2015.
So far 41% of patients have merlin low tumors, which is consistent with the Company’s assumptions
Interim analysis to define the primary patient population is expected in Q2 2015
Encouraging data from our Phase 2 clinical trial evaluating single agent VS-6063 in patients with previously treated KRAS-mutated NSCLC
Study is enrolling well at 9 U.S. sites
Accrual has completed in 2 cohorts; expect to enroll and dose the remaining cohorts in H1 2015
The two cohorts that have been fully enrolled have also crossed the interim analysis threshold of greater than or equal to 4 patients, out of 11, with greater than or equal to 12 week PFS
All cohorts have patients still on study
Long-term use is generally well tolerated
Disease control exceeding 6 months for some patients
Next steps to be determined once all cohorts are complete
Expect to submit study results for presentation at a scientific meeting in H2 2015
Reported updated Phase 1/1b data for VS-6063 in combination with paclitaxel in ovarian cancer
Combination therapy was generally well-tolerated with no dose limiting toxicities
Early signs of clinical activity; 64% best response of stable disease at 8 weeks or better including two complete responses and three partial responses
5 patients continue on study with 3 patients continuing past 12 months to date. The longest patient on study, who has had a Complete Response, has been on VS-6063 for more than 18 months
Treatment with VS-6063 resulted in decreased pFAK activity and a reduction in markers of cancer stem cells in 4 of 5 patient biopsies following 10 days of VS-6063 treatment
Expect to report an update on the study in H2 2015
Reported preliminary data from the biomarker “Window of Opportunity” study in mesothelioma
Single agent VS-6063 was given for 12 days, with pre- and post-treatment biopsies, to patients prior to surgery for malignant pleural mesothelioma
VS-6063 was well tolerated and reduced FAK activity (pFAK-Y397) by an average of 70% in patients evaluated to date and reduced markers of cancer stem cells in post-treatment biopsies in 5 out of 7 patients with evaluable paired biopsies
Measurement of tumor size using RECIST modified for mesothelioma by CT/PET confirmed that there was no progression of disease while on the 12 day treatment with VS-6063 in any of the 10 patients
Tumor shrinkage consistent with a partial response (-30% and -49%) was seen in 2 patients
The study has been amended to increase the VS-6063 treatment period from 12 to 35 days: an additional 10-15 patients are anticipated at this schedule
Expect to report preliminary data on the extended treatment cohort in H1 2016
Completed Phase 1 in Japanese patients; reported preliminary data
VS-6063 was well tolerated at all dose levels; no serious adverse events or dose-limiting toxicity
Confirmed the recommended Phase 2 dose as 400mg BID, consistent with dosing in other patient populations
Opened Japanese sites for the COMMAND study which facilitates a parallel regulatory pathway with other countries in development worldwide
The Japanese subjects included 1 patient with relapsed mesothelioma who had a symptom improvement and PFS of 5.6 months
VS-4718 (Oral Focal Adhesion Kinase Inhibitor)
Phase 1 clinical trial ongoing in patients with advanced solid tumors
Open-label, dose escalation study; designed to assess the safety, pharmacokinetics, pharmacodynamics, maximum tolerated dose and initial clinical activity of single agent VS-4718
Maximum tolerated dose has not yet been reached
Generally well tolerated with patients on treatment for over 6 months
Two patients with mesothelioma have had disease control for greater than 5 months
Expect to report preliminary data in H2 2015
Reported supportive preclinical data at AACR, EORTC, and ASH
Published supportive preclinical data in the journals Science Translational Medicine and Blood
Acquired additional license rights to VS-4718, reducing future milestones and royalties associated with ongoing development
VS-5584 (Oral Dual mTORC 1/2 and PI3K Inhibitor)
Phase 1 dose escalation clinical trial ongoing in patients with advanced solid tumors
Open-label, dose and schedule finding study; designed to assess the safety, pharmacokinetics, pharmacodynamics, maximum tolerated dose and initial clinical activity of single agent VS-5584
Generally well tolerated and the expected on-target toxicities are clinically manageable
Maximum tolerated dose has not yet been reached
Clinical activity observed in multiple tumor types, including mesothelioma; observed disease control of over 6 months
Expect to report preliminary data in H2 2015
Presented supportive preclinical data at iMig demonstrating the synergistic activities of VS-5584 and VS-6063 in cellular and animal models of mesothelioma
Planned clinical trial to evaluate combination of VS-5584 and VS-6063 in relapsed mesothelioma
Expect to begin enrollment in Q1 2015
Reported supportive preclinical data at AACR, EORTC and published supportive preclinical data in Molecular Cancer Therapeutics
Japanese patent issued with claims covering the composition of matter and VS-5584’s ability to inhibit and regulate cellular metabolism, growth, and proliferation
Leadership team
Industry veterans, Timothy J. Barberich, founder of Sepracor, and Paul A. Friedman, M.D., former CEO of Incyte Corporation (INCY), appointed to Verastem Board of Directors
Daniel Paterson, former Verastem Chief Business Officer, promoted to Chief Operating Officer
Summary of Upcoming Milestones
Verastem’s planned upcoming milestones include:
VS-6063
Report COMMAND interim analysis: Q2 2015
Report Phase 2 results in KRAS-mutated NSCLC: H2 2015
Report updated results from the VS-6063/paclitaxel combination in patients with ovarian cancer: H2 2015
Report on the biomarker “Window of Opportunity” study with preliminary results from the extended treatment cohort: H1 2016
VS-4718
Report preliminary Phase 1 results in patients with advanced solid tumors: H2 2015
VS-5584
Initiate clinical trial evaluating combination of VS-5584 and VS-6063 in relapsed mesothelioma: Q1 2015
Report preliminary Phase 1 results in patients with advanced solid tumors expected: H2 2015
Conference Call Information
The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or (315) 625-3226 (international), and entering passcode 60568979. To access the live slide presentation, please use either the following link: http://bit.ly/1vYH8yN or visit the investors section of the Verastem website at www.verastem.com.
Not everyone is a wrench on a construction site. You'd be surprised at how many bachelor degree and higher qualified jobs don't drug test. This has been and will always be a null argument.
Thank you
My opinion is that this marketing campaign will help to drive a big increase in Q1 sales
This marketing campaign is definitely not a fluff. That is a big time ad campaign. Those are some of the most viewed channels in the US and up until now all the advertised with was Twitter and newspaper inserts. This may not be the cbd news but it certainly is not fluff.
Read the quote you provided again